### SUPPLEMENTAL MATERIAL

# **Supplementary Methods**

## Panel membership and workflow

DCM gene curation activities were carried out by an international, multi-site Panel of individuals with expertise in laboratory science, molecular diagnostics, research, and/or clinical care in idiopathic DCM. The Panel, termed "The DCM Gene Curation Expert Panel," a sub-working group of the ClinGen Cardiovascular Clinical Domain Working Group, was composed of 34 individuals from over 20 institutions representing 7 countries (United States, Canada, Netherlands, Australia, United Kingdom, Switzerland, and Italy). Using the ClinGen standard operating procedure (SOP) version 7 (https://clinicalgenome.org/docs/summary-of-updates-to-the-clingen-gene-clinical-validity-curation-sop-version-7/), curators scored available evidence and prepared a presentation for full Panel review, discussion, and approval during a biweekly conference call between September 2019 and October 2020 to establish a final classification. Curated data was entered into a web interface, the Gene Curation Interface (GCI), to organize and record evaluated evidence.

# Development of the DCM gene list

To develop a comprehensive list of genes thought to have a role in the development of DCM in humans, a comprehensive search was conducted in three National Center for Biotechnology Information database resources in October 2017: Gene (https://www.ncbi.nlm.nih.gov/gene), Online Mendelian Inheritance in Man (OMIM)<sup>1</sup> (https://www.ncbi.nlm.nih.gov/omim), and GenBank<sup>2</sup> (https://www.ncbi.nlm.nih.gov/genbank/). Starting with Gene, the search terms "dilated cardiomyopathy" OR "cardiomyopathy, dilated" were applied and limited to Homo Sapiens to identify 199 genes. A subsequent search in OMIM

### Jordan, DCM Gene Curation

and GenBank using the same search terms, limiting to Animals and Genomic DNA/RNA as the molecule type, identified a list of 204 genes. This initial list was further expanded when adding additional genes not identified in the database query from an expansive DCM gene list that had been previously published<sup>3</sup>, which added 63 genes. The full initial list included 267 genes.

Each gene was then manually evaluated by performing a PubMed search of the "[GENE]" AND "dilated cardiomyopathy" in addition to "[GENE]" AND "cardiomyopathy, dilated" to identify relevant publications proposing a role in the development of idiopathic DCM in humans (May 2018). Genes were removed for the following reasons: those specified as possible candidate genes without supporting animal or human genetic evidence; those that did not have published evidence in human idiopathic DCM; those described as primarily part of a syndrome; and those primarily observed in other non-DCM cardiovascular diseases. Following the application of these criteria, 56 genes remained.

Genes implicated in more than one disease underwent precuration to confirm the DCM disease entity and mode of inheritance for each gene curated

(https://clinicalgenome.org/working-groups/lumping-and-splitting/). Precurations were performed to identify the disease entity and mode of inheritance. Precurations were shared with the Panel for review prior to formal preparation and scoring of evidence to assign a gene-disease validity classification. During this process, five genes were removed from the curation schedule due to syndromic disease entity (*SDHA*), lack of sufficient evidence specific to the DCM phenotype as defined for this curation effort (*DSC2, GATA4, GATA6*), or a different cardiomyopathy sub-type as the primary disease entity without a clear assertion for an isolated DCM phenotype in a single gene-disease relationship (*ALPK3*). The remaining 51 genes represent the final gene list (June 2019) (Figure S1).

2

Five of the genes on the final list were identified as predicted to be classified as definitive (*BAG3, LMNA, MYH7, TNNT2,* and *TTN*) and therefore underwent an expedited curation, requiring the review and approval of two Panel members of the evidence review in an offline mechanism, followed by review and approval of the evidence summary by the full Panel prior to publishing. In addition, two genes had been recently curated by the Hypertrophic Cardiomyopathy Gene Curation Expert Panel (HCM GCEP) for an applicable disease entity, intrinsic cardiomyopathy (MONDO:0000591), and mode of inheritance prior to the DCM gene curation project (*PLN*, <u>https://search.clinicalgenome.org/kb/gene-validity/8772</u>; *ACTN2* <u>https://search.clinicalgenome.org/kb/gene-validity/8772</u><sup>4</sup>. The other 44 genes underwent the standard curation process.

# Curation of Published Evidence

Evaluation of genetic evidence included publications presenting clinical data for patients, families, and large cohorts that could be consider for scoring of individual variants, segregation in pedigrees, and case-control analyses. A minor allele frequency (MAF) cut-off for the maximum credible frequency to have a pathogenic effect was calculated using an allele frequency calculator which integrates disease prevalence, mode of inheritance, genetic and allelic heterogeneity, and penetrance (https://www.cardiodb.org/allelefrequencyapp/).<sup>5</sup> We sought to produce a conservative estimate consistent with Mendelian, autosomal dominant disease, occurring at a prevalence 1/250 individuals in the population<sup>6</sup>. While reduced penetrance is commonly observed in DCM, penetrance estimates are not widely available. Further, the penetrance of the genes included in the curation list are anticipated to vary widely, therefore, estimates of 20-40% penetrance were considered. DCM is also highly heterogeneous, with no single variant causing more than 1-2% of DCM cases. Taking these values into consideration, a

3

### Jordan, DCM Gene Curation


maximum credible population allele frequency of 0.0001 was generated, consistent with the clinical standard<sup>7</sup> for monogenic DCM. Variants with a MAF <0.0001 were scored in the curation of genetic evidence.

Experimental evidence was assessed by category (expression data, functional alterations, model systems, and rescue). Expression evidence prioritized studies of human cardiomyocytes or animal models as an alternative when human models were not available. Model systems assessing the disruption to the gene in consideration demonstrated a phenotype suggestive of DCM, and rescue models using cell-culture or non-human animal models with DCM could be rescued by restoring wild-type gene product. Experimental data only evaluating rare variants with some evidence of impact were scored.

Genes with a score reaching a strong classification that demonstrated replication over time in the literature, as defined by at least three years since original publication and at least two independent supporting publications, were classified as definitive. Limited evidence genes lack substantial evidence supporting the gene-disease relationship, however, data challenging the relationship is also not present, and therefore while the role in monogenic disease is not supported based on currently available evidence, the clinical relevance of these genes is not ruled out. Genes were classified as disputed when evidence was deemed insufficient and panel opinion and/or literature questioned the biological relevance of the gene in the disease. Genes classified as no known disease relationship and animal model only represent candidate genes that do not yet have sufficient human data to evaluate for a clinical classification.

4

# **Supplemental Figure**



**Figure S1**. **DCM gene list filtering.** An original list of 267 genes, generated by OMIM, Gene, and GenBank database queries combined with a previously published DCM gene list<sup>3</sup>, was filtered down to a list of 51 genes indicated in humans with isolated, idiopathic DCM that proceeded through the gene curation process. CV = cardiovascular; DCM = dilated cardiomyopathy.

# **Supplemental References**

- Hamosh A, Scott AF, Amberger JS, Bocchini CA, McKusick VA. Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders. *Nucleic Acids Res.* 2005;33(Database issue):D514-517.
- Benson DA, Karsch-Mizrachi I, Clark K, Lipman DJ, Ostell J, Sayers EW. GenBank. Nucleic Acids Res. 2012;40(Database issue):D48-53.
- McNally EM, Mestroni L. Dilated Cardiomyopathy: Genetic Determinants and Mechanisms. *Circ Res.* 2017;121(7):731-748.
- Ingles J, Goldstein J, Thaxton C, et al. Evaluating the Clinical Validity of Hypertrophic Cardiomyopathy Genes. *Circ Genom Precis Med.* 2019.
- 5. Whiffin N, Minikel E, Walsh R, et al. Using high-resolution variant frequencies to empower clinical genome interpretation. *Genet Med.* 2017;19(10):1151-1158.
- 6. Hershberger RE, Hedges DJ, Morales A. Dilated cardiomyopathy: the complexity of a diverse genetic architecture. *Nat Rev Cardiol*. 2013;10(9):531-547.
- Nykamp K, Anderson M, Powers M, et al. Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria. *Genet Med.* 2017;19(10):1105-1117.

Supplemental Table 1: Gene List Filtering

ORIGINAL LIST	McNally 2017 (PMID		REMOVED-	REMOVED- NOT	REMOVED - NOT IDIOPATHIC DCM	REMOVED		
(OMIM; GENE;	28912180)		MT/METABOLIC/	IDIOPATHIC DCM	(NON-CV	REMOVED - PRECURATION	REMOVED - OTHER	FINAL LIST
GenBank)	28512180)	(ALL)	SYNDROMIC	(OTHER CM/CV DZ)	DZ/syndrome)	FRECORATION	OTHER	
АВСС9	ABCC9				D2/ Synaronic/			АВСС9
ACADVL		ACADVL	ACADVL					
ACE		ACE			ACE			
ACTC1	ACTC1							ACTC1
ACTN2	ACTN2							ACTN2
ADIPOQ		ADIPOQ	ADIPOQ					
ADORA1		ADORA1			ADORA1			
ADRA2C		ADRA2C		ADRA2C				
ADRB1		ADRB1		ADRB1	40000			
ADRB2	4.61	ADRB2 AGL	AGL		ADRB2			
AGT	AGL	AGL	AGL		AGT			
AGTR1		AGTR1			AGTR1			
ALMS1	AI MS1	ALMS1	ALMS1		AGINI			
		ALPK3				ALPK3		
ANKRD1	ANKRD1							ANKRD1
ANO5		ANO5	ANO5					
AR		AR			AR			
BAG3	BAG3							BAG3
BCL2		BCL2					BCL2	
BMP4		BMP4			BMP4			
	BRAF	BRAF	BRAF					
BTNL2		BTNL2		BTLN2				
	CACNA1C	CACNA1C		CACNA1C				
CACNG8		CACNG8					CACNG8	
	CALR3	CALR3					CALR3	
CASK		CASK			CASK			
	CASQ2	CASQ2		CASQ2				
CASZ1	CAN/2	CASZ1		CAN/D			CASZ1	
CAVIN4		CAV3		CAV3				
CAVIN4 CD34	(IVIURC)	CAVIN4/MURC CD34					REPEAT (MURC) CD34	
CD34 CD40LG		CD40LG			CD40LG		CD34	
CD46		CD46			CD46			
CDH2		CDH2	CDH2		6040			
CHGA		CHGA	00112				CHGA	
	CHRM2	CHRM2					CHRM2	
CHRM3		CHRM3			CHRM3			
CMD1B		CMD1B					CMD1B	
CMD1H		CMD1H					CMD1H	
CMD1K		CMD1K					CMD1K	
CMD1Q		CMD1Q					CMD1Q	
	CPT2	CPT2	CPT2					
CRP		CRP					CRP	
CRYAB	CRYAB	CRYAB	CRYAB					
CSRP3	CSRP3							CSRP3
	CTF1							CTF1
CTLA4		CTLA4			CTLA4			
CTNNA3	CTNNA3	CTNNA3		CTNNA3				
СТЅВ		СТЅВ			СТЅВ			
CTSL		CTSL					CTSL	
CX3CR1		CX3CR1		CX3CR1				
CXADR		CXADR			CXADR			
CYP2E1		CYP2E1			CYP2E1			
DAG1		DAG1	DAG1					
DES	DES							DES
DMD		DMD	DMD					
DNAJC19		DNAJC19	DNAJC19					
DSC2		DOLK DSC2	DOLK			DSC		
DSC2 DSG2	DSC2					Dac		DSG2
0302	DSG2							DSP
	DSP							DTNA
EDN1	DINA	EDN1		EDN1				
EDN1 EDNRA		EDN1 EDNRA		LUNI	EDNRA			
EDNRB	EN 4D	EDNRB	EMD		EDNRB			
	EMD	EMD	EMD					
ERBB2		ERBB2			ERBB2			
ESR1		ESR1		ESR1	5600			
ESR2		ESR2			ESR2			

I I		<b>I</b>			I			
ESRRB		ESRRB			ESRRB			
EYA4	EYA4				546			EYA4
FAS		FAS			FAS			
FBXO32		FBXO32					FBXO32	
FHOD3		FHOD3					FHOD3	
		FHL1	FHL1					
		FHL2		FHL2				
FKRP		FKRP	FKRP					
FKTN	FKTN	FKTN	FKTN					
FLNC	FLNC							FLNC
FN1		FN1			FN1			
FOXD4		FOXD4					FOXD4	
	FRDA/FXN	FRDA/FXN	FRDA/FXN					
	GAA	GAA	GAA					
GATA4	GATA4	GATA4				GATA4		
GATA6	GATA6	GATA6				GATA6		
GATAD1	GATAD1							GATAD1
GBE1		GBE1	GBE1					
GDF1		GDF1		GDF1				
GJA4		GJA4					GJA4	
	GLA	GLA	GLA					
HAND1		HAND1					HAND1	
HAVCR1		HAVCR1					HAVCR1	
		HCN4		HCN4				
HFE	HFE	HFE		HFE				
HLA-DQB1		HLA-DQB1			HLA-DQB1			
HLA-DRB1		HLA-DRB1			HLA-DRB1			
HLA-DRB4		HLA-DRB4					HLA-DRB4	
HLA-G		HLA-G			HLA-G			
		НОРХ					НОРХ	
	HRAS	HRAS	HRAS					
HSPD1		HSPD1			HSPD1			
IFIH1		IFIH1			IFIH1			
IFNG		IFNG			IFNG			
IGF1		IGF1			IGF1			
IL10		IL10			IL10			
IL17A		IL17A					IL17A	
IL17F		IL17F			IL17F			
IL1B		IL1B			IL1B			
IL2RA		IL2RA			IL2RA			
IL6		IL6			IL6			
120	ILK							ILK
ITGA6		ITGA6			ITGA6			
ITGB1BP2		ITGB1BP2			110/10		ITGB1BP2	
ITGB1BF2		ITGB1BF2			ITGB4		ITODIDF2	
					11064			
ITLN1		ITLN1 ITPR2					ITLN1	
ITPR2					ITPR2			JPH2
	JPH2	JUP						JPHZ
KO1144	JUP			JUP	KONIAA			
KCNJ11		KCNJ11			KCNJ11		KONIAS	
KCNJ12		KCNJ12		KONIO			KCNJ12	
KCNJ2		KCNJ2		KCNJ2	KONNO			
KCNN3		KCNN3		KONOA	KCNN3			
KCNQ1		KCNQ1		KCNQ1				
		KRAS	KRAS					
LAMA2		LAMA2	LAMA2					
LAMA4	LAMA4							LAMA4
LAMP2	LAMP2	LAMP2	LAMP2					
LCN2		LCN2					LCN2	
LDB3	LDB3							LDB3
LGALS3		LGALS3					LGALS3	
LMNA								LMNA
LRP1		LRP1			LRP1			
LRRC10	LRRC10							LRRC10
LRRC32		LRRC32					LRRC32	
LTBP4		LTBP4			LTBP4			
	MAP2K1	MAP2K1	MAP2K1					
		MAP2K2	MAP2K2					
MAPK14		MAPK14					MAPK14	
	MIB1							MIB1
MIR199A1	IVIDI	MIR199A1					MIR199A1	
MIR199A1 MIR208A		MIR199A1 MIR208A					MIR199A1 MIR208A	
		MIR208A MIR214					MIR208A MIR214	
		14111/214						
MIR214							N/ID/15 A	
MIR214 MIR451A MLIP		MIR451A MLIP					MIR415A MLIP	

		_	_				
MMP1		MMP1			MMP1		
MMP10		MMP10				MMP10	
MMP14		MMP14			MMP14		
MMP3		MMP3		MMP3			
MMP7		MMP7				MMP7	
MMP9 MT-TI		MMP9 MT-TI	MTTI		MMP9		
IVI I - I I		MTND1	MTND1				
		MTND1 MTND5	MTND1 MTND5				
		MTND6	MTND6				
		MTTD	MTTD				
		MTTG	MTTG				
		MTTH	MTTH				
		MTTI	MTTI				
	MTTK	МТТК	MTTK				
	MTTL1	MTTL1	MTTL1				
	MTTL2	MTTL2	MTTL2				
	MTTM	MTTM			MTTM		
		MTTQ			MTTQ		
		MTTS1			MTTS1		
		MTTS2			MTTS2		
CAVIN4	MURC	MURC/CAVIN				MURC/CAVIN	
MYBPC1		MYBPC1			MYBPC1		A AVADOCA
MYBPC3 MYC	МҮВРС3				MYC		МҮВРС3
MYC MYH6	МҮН6	MYC			МҮС		МҮН6
МҮН5 МҮН7	MYH7						МҮНБ МҮН7
MYL2	MYL2						MYL2
	MYL3						MYL3
		MYLK2		MYLK2			
MYOM1		MYOM1		MYOM1			
	MYOZ2	MYOZ2		MYOZ2			
MYPN							MYPN
NAMPT		NAMPT				NAMPT	
NDUFV1		NDUFV1			NDUFV1		
NEBL	NEBL						NEBL
NEXN	NEXN						NEXN
NFKB1		NFKB1			NFKB1		
NLRP3	NKX2-5	NLRP3			NLRP3		NKX2-5
NOS3		NOS3			NOS3		
NPPA	NPPA				1055		NPPA
NPPB		NPPB				NPPB	
NPPC		NPPC			NPPC		
NPR2		NPR2			NPR2		
NR3C2		NR3C2			NR3C2		
	NRAS	NRAS	NRAS				
OBSCN							OBSCN
OSM		OSM				OSM	
PDCD1		PDCD1			PDCD1	0050	
PDE2A		PDE2A			00524	PDE2A	
PDE3A	PDLIM3	PDE3A			PDE3A		PDLIM3
PGM1	PDLINI3	PGM1	PGM1				- SEIVIS
	РКР2						РКР2
PLEC1		PLEC1	PLEC				
PLEKHM2	PLEKHM2						PLEKHM2
PLN	PLN						PLN
PNPLA2		PNPLA2	PNPLA2				
POLG		POLG	POLG				
PPP1R13L		PPP1R13L				PPP1R13L	
PRDM16	PRDM16			DDKA C2			PRDM16
PSEN1	PRKAG2	PRKAG2		PRKAG2			PSEN1
PSEN1 PSEN2							PSEN1 PSEN2
JLIVZ	PTPN11	PTPN11	PTPN11				I JLIVZ
	FIFNII		RAF1				
			(Noonan/Rasopath				
RAF1	RAF1	RAF1	y)				
RARRES2		RARRES2				RARRES2	
RBM20	RBM20						RBM20
			RIT1				
		1	(noonan/rasopathy				
RYR2		RIT1 RYR2	)	RYR2			

SCN5A	SCN5A							SCN5A
SDHA	SDHA		SDHA			SDHA		SCINSA
SDHA SERPINE1	SURA	SERPINE1	SDHA		SERPINE1	SURA		
SERFINEI	SGCA		SGCA		JERPINEI			
	SGCA		SGCA					
500D		SGCB	SGCB					600D
SGCD	SGCD SGCG	5000	SGCG					SGCD
5CK4	SGCG		SGCG				CCK4	
SGK1	CL C2245	SGK1	CI C2245				SGK1	
	SLC22A5		SLC22A5				CI COF A 5 DO	
SLC25A5P8		SLC25A5P8					SLC25A5P8	
SOD2	SOD2						SOD2	
	SOS1		SOS1					
SPEG		SPEG	SPEG					
SRF		SRF					SRF	
STAT3		STAT3			STAT3			
SYNE1		SYNE1	SYNE3					
	SYNM	SYNM					SYNM	
TAX1BP3		TAX1BP3					TAX1BP3	
TAZ	TAZ	TAZ	TAZ					
TBX20	TBX20							TBX20
TBX5		TBX5			TBX5			
ТСАР	TCAP							ТСАР
TFAP2A		TFAP2A			TFAP2A			
TGFB1		TGFB1			TGFB1			
	TGFB3	TGFB3		TGFB3				
TIMP1		TIMP1					TIMP1	
TIMP4		TIMP4					TIMP4	
	TMEM43	TMEM43	TMEM43					
тмро		ТМРО					тмро	
TNC		TNC			TNC			
TNF		TNF			TNF			
TNFRSF11B		TNFRSF11B			TNFRSF11B			
TNFRSF12A		TNFRSF12A					TNFRSF12A	
TNFSF10		TNFSF10					TITNFSF10	
TNFSF12		TNFSF12					TNFSF1	
TNNC1	TNNC1							TNNC1
TNNI3	TNNI3							TNNI3
тллізк	тллізк							тллізк
TNNT2	TNNT2							TNNT2
TP53		TP53			TP53			
TPM1	TPM1							TPM1
	TRDN	TRDN		TRDN				
TRPV2		TRPV2					TRPV2	
TTN	TTN							TTN
	TTR	TTR		TTR				
TWIST1		TWIST1			TWIST			
TXNRD2	TXNRD2		TXNRD2					
VCL	VCL							VCL
VEGFA	VCL	VEGFA			VEGFA			
VLOIA		VLOIA			VLOIA		REPEAT - SEE	
ZASP		ZASP					LDB3	
ZASP ZBTB17		ZASP ZBTB17					ZBTB17	
			TOTAL: FF	TOTAL: 20	TOTAL 70	TOTAL		TOTAL - 51
TOTAL: 204	TOTAL: 63 (125-62)		TOTAL: -55	TOTAL: -26	TOTAL: -70	TOTAL: -5	TOTAL: -60	TOTAL: 51
TOTAL REFO	RE REMOVED: 267	TOTAL AFTER		TOTAL OF ALL R	EMOVED CATEGOR	IFS: 216		TOTAL FINAL
		REMOVED: 51		LIST: 51				

#### Jordan, DCM Gene Curation

#### Supplemental Table 2: DCM Panel Composition

DCM	Curated	USA:	USA: EGL	USA:	USA:	USA:	Finland:	USA:	USA:	Spain:	USA: Knight	Spain:	USA:	Germany:	Germany:	Canada:	USA:	Panel	% Panels
Classification	Genes	Invitae	Genetic	Prevention	Cincinnati's	Ambry	Blueprint	Fulgent	Washington	Health in	Diagnostic	CGC	Gene Dx	CeGaT	MGZ -	LifeLabs	Sema4	Totals	Present
			Diagnostics	Genetics	Childrens	Genetics	Genetics	Genetics	University	Code	Laboratories	Genetics		GmbH	Medical	Genetics			
					Hospital										Genetics				
															Center				
- (1.1.1																			
Definitive	BAG3	1																	
	DES	1													_		1		
	LMNA	-	-	1		-						-					1		
	MYH7 PLN	1		-									1				1		
	RBM20	1	-	1				-							_	-	1		
	SCN5A	1	-	1								-							
	TTN	1															1		
	TNNC1	1	-	1												-	1		
	TNNC1 TNNT2	1	-	-							-				-	-			
	FLNC	1						-					1				1		
	FLINC	1	. 0	1	. <u> </u>	. <u> </u>				. <u> </u>		/ <u>1</u>	1	. <u> </u>	0		1	. 12	
Strong	DSP	1	1	1	. 1	. 0	1	1		1	1	. 1	1	. 1	1	1	1		
Strong	D3P	1	. <u> </u>	1	. <u> </u>	. 0				1		· · ·	1	. <u> </u>	<sup>-</sup>		1	. 14	
Moderate	ACTC1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	. 16	
Widderate	TNNI3	1	1	1	1	. 1	1	1	1	1	1	. 1	-	-	-	1	1	1	
	TPM1	1	-	1		. 1				-	1	. 1					1		
	VCL	1	1	1	. 1	1		1	1		1	1	1		1	-	1		
	ACTN2	0	1	1	1	1		. 1	-		1	. 1	1		1	-	-	1	
	NEXN	1		1		. 1				-		. 1					1		
	JPH2	0	-	0		. 0		1					-		0	-			
	51.112		0	0	, 1	. 0		<u> </u>		0				· <u> </u>				,	
Limited	ABCC9	1	1	1	. 1	. 1	1	1	1	. 1	1	. 1	1	1	1	1	1		
Linneed	LDB3	1	-	1		1		-				. 1			_		1		
	MYBPC3	1	1	1				-	-		-						1	-	
	MYH6	1	=	1													1		
	ТСАР	1	1	1		1		-	-		1	1					1		
	ANKRD1	1	1	1				) 1			1	. 1					1	-	
	CSRP3	1	1	1													1		
	LAMA4	1	1	1		1			-		1	1	-				1		
	MYPN	1	1	1				) 1			1	. 1					1		
	DSG2	1	1	1									1				1	-	
	GATAD1	1	1	1	. 1	. 0		) 1	1	1	1	. 1	1	1	1	1	1		
	ILK	1	. 0									. 1	1				1		
	NEBL	1	1	1		. 0						. 1				1	1		
	PRDM16	1	1	1				1		1	0	) 1			1	. 1	1		
	SGCD	0	1														1		
	EYA4	1	. 0	1		. 0					1	. 1				. 1	1		
	NKX2-5	1	. 0	1				1	. 1	. 1	0	) 1			0	0			
	TBX20	0	0			. 1		L 1	. 1	. 1	0	0 0	1	. 0	1	. 1	C		
	DTNA	0	0	1		. 0		) 1		1	0	0 0			0	0	C	5	
	MYL2	0	0			. 0	C	) 1	. C	1	0	) 1	C	1	0	0	C	) 5	31.3%
	CTF1	1	. 0	1		0	C	) 1	. 1	. 0	0	) 1	C	0	0	0	C	) 4	-
	PLEKHM2	1	. 0	0	0 0	0	1	L C	1	. 0	0	0 0	C	0	0	0	C	) 3	18.8%
	PSEN2	0	0			0	C	) C	C	1	C	) 1	C	0	1	. 0	C	) 3	18.8%
	TNNI3K	0	0	0	0 0	1	. 1	L C	C	1	0	0 0	C	0	0	0	C	) 3	
	OBSCN	0	0	0	0 0	0	C	) C	C	1	0	0 0	C	0	0	0	1	. 2	12.5%
																		C	0.0%
Disputed	PDLIM3	1	. 1	1	. 1	. 0	C	) 1	1	. 1	1	. 1	C	1	1	. 1	C	12	75.0%

	PKP2	1	0	1	1	0	1	. 1	0	1	1	1	0	1	1	1	1	12	75.0%
	MYL3	0	0	0	1	0	0	1	0	1	0	1	0	1	0	0	0	5	31.3%
	PSEN1	0	0	0	0	0	0	0	0	1	0	1	0	0	1	0	0	3	18.8%
																		0	0.0%
No Known Dise	MIB1	0	0	1	1	0	0	1	0	1	0	0	1	0	0	0	0	5	31.3%
	LRRC10	1	0	0	1	0	1	. 0	1	0	0	0	1	0	0	0	0	5	31.3%
	NPPA	1	0	0	0	0	0	1	1	0	0	1	0	0	0	0	0	4	25.0%